Robert Brown

Robert Brown

Company: Imperial College London

Job title: Professor


Robert (Bob) Brown is Professor of Translational Oncology, Imperial College London, with a joint post in the Institute of Cancer Research, London. Until recently, he was Head of Division of Cancer at Imperial College.  Bob’s research focuses on epigenetics of cancer and drug resistance, with a focus on ovarian cancer. He facilitates development of novel epigenetic therapies and is using biomarkers to aid their preclinical and early clinical development. Current research interests include the effect of DNA damaging agents on the epigenome, preclinical development of histone methyltransferase inhibitors and epigenetic targets to prevent acquisition of drug resistance.



Panel: Combination Therapies vs Monotherapies – Approaches with epigenetic therapies 12:30 pm

Can HDAC inhibitors really work as a monotherapy? Clinical trial implications of combination therapiesRead more

day: Virtual Conference Day

Targeting epigenetic adaptation in ovarian cancer 11:30 am

Improving treatment of ovarian cancer is a major clinical unmet need. Epigenetic adaptation is a driver of drug resistance in ovarian cancer. Potential of histone methyltransferases to overcome drug resistance. Modulation of the immune microenvironment by histone methyltransferases.Read more

day: Virtual Conference Day

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.